Eli Lilly and Company...announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. (PRNewswire) - Oct 25, 2026 - "Results shared in a poster presentation from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial of olomorasib plus Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab), without chemotherapy, in first-line KRAS G12C-mutant non-small cell lung cancer (NSCLC) show that median progression-free survival (PFS) and duration of response (DOR) had not been reached after a median follow-up of nearly 21 months, with durable activity observed across PD-L1 levels...The most common Grade 3 or higher treatment-related adverse events (TRAEs) were increased ALT (15.3%), increased AST (12.9%) and diarrhea (8.2%)...Lilly expects first randomized Phase 3 data from SUNRAY-01 in first-line KRAS G12C-mutant NSCLC in the first half of 2027."
P1/2 data • P3 data • Non Small Cell Lung Cancer • Solid Tumor
|